Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Transitional Cell 29Carcinoma, Non-Small-Cell Lung 29Urinary Bladder Neoplasms 26Neoplasms 22Carcinoma, Renal Cell 22Carcinoma, Merkel Cell 21Neoplasm Metastasis 18Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Drug Therapy 3Temozolomide 2Radiotherapy 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Semen Analysis 1Registries 1Probiotics 1Patient Reported Outcome Measures 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Second Primary × avelumab × Clear all
NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Ludwig-Maximilians - University of Munich

Phase 2 Completed
57 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡